Live Analyst Rating Changes 24314 upgrades, downgrades & price-target moves · freshest Wall Street data, updated daily View live feed →
Analyst Tracker/Charles Pitman CFA
BARC

Charles Pitman CFA

Wall Street Analyst
★★★★★
#243
on 13Foresight · ranked by our own returns
81%
Success Rate
+9.1%
Average Return
21 of 26 calls profitable · +1.6% vs benchmark
S&P 500 (SPY)
📈 Across the calls we could measure, roughly 81% of Charles Pitman CFA's ratings turned a profit when each position was held for 1 year — averaging +9.1% per rating. These figures are computed by 13Foresight from historical prices, not supplied by the analyst.

Rating Distribution

82 Buy 29 Hold 4 Sell
Charles's Stock Coverage 20 ratings · 2026-08-13
Company Date Position Consensus Price Target 1-Yr Return vs S&P 500
CH:LONN
Lonza Group Ltd
Aug 07, 2026 BUY Strong Buy
+13.9% avg upside
21 analysts
$680.00
20.60% Upside
· ·
DE:MRK
Merck KGaA
Aug 07, 2026 HOLD Buy
-1.7% avg upside
33 analysts
$140.00
0.59% Upside
· ·
GB:0NZT
UCB SA
Aug 03, 2026 HOLD Buy
-0.9% avg upside
19 analysts
$260.00
15.21% Upside
· ·
IT:REC
Recordati Industria Chimica e Farmaceutica SPA
Jul 30, 2026 HOLD Hold
-8.4% avg upside
7 analysts
$50.00
5.18% Downside
+1.9% ·
DE:BAYN
Bayer
Jul 14, 2026 BUY Strong Buy
+8.6% avg upside
30 analysts
$60.00
22.87% Upside
+3.5% ·
FR:BIM
bioMerieux
Jun 23, 2026 HOLD Buy
+34.7% avg upside
12 analysts
$80.00
9.47% Upside
+6.4% ·
CH:PPGN
PolyPeptide Group AG
Jun 16, 2026 BUY Strong Buy
-20.4% avg upside
3 analysts
$40.00
9.13% Downside
+20.2% ·
CH:BANB
Bachem Holding AG
Jun 09, 2026 HOLD Sell
-1.1% avg upside
4 analysts
$70.00
4.84% Downside
+8.6% ·
DE:SRT3
Sartorius
Apr 23, 2026 BUY Buy
+15.7% avg upside
18 analysts
$270.00
14.50% Upside
+5.7% ·
FR:DIM
Sartorius Stedim Biotech
Apr 23, 2026 BUY Strong Buy
+38.2% avg upside
11 analysts
$220.00
22.25% Upside
+7.4% ·
ES:GRF
Grifols
Apr 22, 2026 BUY Buy
+46.3% avg upside
12 analysts
$12.50
23.83% Upside
+14.0% ·
CH:SDZ
Sandoz Group Ltd
Mar 11, 2026 HOLD Buy
-7.0% avg upside
11 analysts
$75.00
4.68% Upside
+19.6% ·
GB:DIA
Dialight
Jan 06, 2026 SELL Strong Sell
1 analyst
-43.2% ·
BAYRY
Bayer
Jan 06, 2026 BUY Buy
+200.0% avg upside
9 analysts
+28.1% ·
IT:DIA
DiaSorin S.p.A.
Jan 06, 2026 SELL Sell
+45.8% avg upside
10 analysts
$60.00
18.90% Downside
-5.7% ·
GB:0QW0
arGEN X
Oct 31, 2025 BUY Strong Buy
-19.1% avg upside
24 analysts
$850.00
11.66% Upside
· ·
FR:IPN
Ipsen
Oct 24, 2025 HOLD Hold
-20.0% avg upside
17 analysts
$125.00
19.18% Downside
+36.9% ·
ARGX
Argenx Se
Apr 28, 2025 BUY Strong Buy
-10.3% avg upside
47 analysts
$751.49
12.98% Downside
+24.8% ·
GRFS
Grifols SA
Jan 04, 2024 BUY Buy
+208.5% avg upside
12 analysts
$20.81
162.42% Upside
-32.1% ·
ABBV
AbbVie
Jan 13, 2022 BUY Strong Buy
-4.0% avg upside
46 analysts
+19.4% ·
🔒 15 more ratings — with price targets, crowd consensus and our measured returns.
Free account unlocks every analyst's full coverage table.
Charles Pitman CFA — Frequently Asked Questions
How accurate are Charles Pitman CFA's stock ratings?
Based on the calls 13Foresight could measure, about 81% of Charles's ratings were profitable over a one-year hold, with an average return of +9.1% per rating, or +1.6% versus the S&P 500. We score every analyst the same way, from historical prices. Each return is measured in the stock's own trading currency, so for non-US listings the S&P 500 comparison leaves out currency moves.
How is Charles ranked on 13Foresight?
Charles Pitman CFA is currently ranked #243 with a 5-star rating. Our rank blends hit rate, average return versus the market, and how many calls we have to judge — so a long, consistent record outweighs a few lucky picks. It is our own calculation, updated daily.
Which stocks does Charles cover?
Charles most recently has ratings on CH:LONN, DE:MRK, GB:0NZT, IT:REC, DE:BAYN, FR:BIM, CH:PPGN, CH:BANB, DE:SRT3, FR:DIM, ES:GRF, CH:SDZ and 8 more. See the full coverage table above for positions, price targets and our measured returns.
Where can I see other analyst ratings?
Browse the full analyst leaderboard to compare Wall Street analysts ranked by their measured performance, success rate and average return.

Disclaimer: 13Foresight compiles analyst ratings and price targets from publicly available sources. Performance metrics, rankings and star ratings shown here are calculated independently by 13Foresight from historical market prices and may differ from figures published elsewhere. This information may be incomplete, delayed or inaccurate, is provided for research and informational purposes only, and is not investment advice. The underlying ratings and opinions are those of the respective analysts and their firms; 13Foresight accepts no liability for any decisions made based on this data.